These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
8. World Hypertension Day 2007. Jones DW; Hall JE Hypertension; 2007 May; 49(5):939-40. PubMed ID: 17420339 [No Abstract] [Full Text] [Related]
9. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related]
10. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors? Miura S; Saku K J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856 [No Abstract] [Full Text] [Related]
11. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732 [TBL] [Abstract][Full Text] [Related]
15. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
16. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon. Verma N; Figueredo VM Am J Ther; 2014; 21(3):222-32. PubMed ID: 22967983 [TBL] [Abstract][Full Text] [Related]
17. CETP Inhibition in CVD Prevention: an Actual Appraisal. Di Bartolo B; Takata K; Duong M; Nicholls SJ Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619 [TBL] [Abstract][Full Text] [Related]
18. The failure of torcetrapib: was it the molecule or the mechanism? Tall AR; Yvan-Charvet L; Wang N Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967 [No Abstract] [Full Text] [Related]
19. Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior. Simko V Bratisl Lek Listy; 2016; 117(11):625-627. PubMed ID: 28125886 [TBL] [Abstract][Full Text] [Related]
20. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]